Dapagliflozin in peritoneal dialysis patients: a pilot study evaluating peritoneal membrane function.

ABSTRACT:

Background

Patients taking SGLT-2 inhibitors may experience delayed peritoneal fibrosis, better ultrafiltration of water and toxins, and higher survival rates. We aimed to evaluate the possible effects of Dapagliflozin in changing the peritoneal solute transfer rate, reducing peritoneal glucose absorption, and, hence, increasing ultrafiltration.

Methodology

A pilot pre-post interventional study was used to evaluate 20 patients on continuous ambulatory peritoneal dialysis (CAPD) enrolled in a one-month self-controlled study [Trial#: NCT04923295]. Inclusion criteria included being over 18, and having a Peritoneal Dialysis (PD) vintage of at least six months. All participants were classified as having high or average high transport status based on their Peritoneal Equilibrium T

SUBMITTER: Hamdan Z 

PROVIDER: S-EPMC10811926 | biostudies-literature | 2024 Jan

REPOSITORIES: biostudies-literature